Table 1.
Baseline characteristics of included studies&.
| Study | Year | Country | Number lost to followup | Followup (months) | Intervention arms | FBG (mg/dL) | Duration of diabetes (years) | HbA1c % | Age (years) | Sample size (F/M, n) | BMI (kg/m2) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dixon et al. [13] | 2008 | Australia | 0 (60) | 24 | Gastric banding + medication | 156 (38.5) | ≤2 | 7.8 (1.2) | 46.6 (7.4) | 15/15 | 37.0 (2.7) |
| Medication | 158 (48.7) | ≤2 | 7.6 (1.4) | 47.1 (8.7) | 17/13 | 37.2 (2.5) | |||||
|
| |||||||||||
| Schauer et al. [14] | 2012 |
USA | 10 (150) | 12 | Gastric bypass | 193 (141, 231)* | 8.2 (5.5) | 9.3 (1.4) | 48.3 (8.4) | 29/21 | 37.0 (3.3) |
| Gastrectomy | 164 (132, 224)* | 8.5 (4.8) | 9.5 (1.7) | 47.9 (8.0) | 39/11 | 36.2 (3.9) | |||||
| Medication | 155 (120, 206)* | 8.9 (5.8) | 8.9 (1.4) | 49.7 (7.4) | 31/19 | 36.8 (3.0) | |||||
|
| |||||||||||
| Mingrone et al. [15] | 2012 | Italy | 10 (60) | 24 | Gastric bypass | 9.55 (3.35)** | 6.03 (1.18) | 8.6 (1.40) | 43.9 (7.57) | 8/12 | 44.85 (5.16) |
| Biliopancreatic diversion | 9.70 (3.44)** | 6.00 (1.26) | 8.88 (1.71) | 42.75 (8.06) | 10/10 | 45.14 (7.78) | |||||
| Medication | 9.94 (3.43)** | 6.08 (1.24) | 8.5 (1.24) | 43.4 (7.27) | 10/10 | 45.62 (6.24) | |||||
&means (SD); FBG: fasting blood glucose; HbA1c: hemoglobin A1c; F/M: female/male; BMI: body-mass index; IQR: interquartile range; *IQR: interquartile range; **mmol/liter.